logo

United Therapeutics Corp (UTHR)



Trade UTHR now with
  Date
  Headline
4/19/2021 6:06:54 AM United Therapeutics Announces Submission Of NDA For Tyvaso DPI To FDA
4/1/2021 6:06:39 AM United Therapeutics Reports FDA Approval And Launch Of Tyvaso For Treatment Of PH-ILD
2/24/2021 6:17:56 AM United Therapeutics Q4 Adj. EPS Rises To $3.31 From $1.96 Prior Year
2/10/2021 6:18:43 AM United Therapeutics Launches Commercial Sales Of Remunity Pump For Remodulin For Patients With PAH
1/28/2021 6:17:27 AM United Therapeutics Says BREEZE Study Of Investigational Tyvaso DPI Meets Primary Objective
5/2/2019 9:42:11 AM Wedbush Is Increasing United Therapeutics Corp (UTHR) FY19 Rev. Estimate To 1310 M From 1274 M
5/2/2019 9:41:46 AM Wedbush Is Cutting United Therapeutics Corp (UTHR) FY20 Estimate To 9.79 From 10.01
5/2/2019 9:41:33 AM Wedbush Is Cutting United Therapeutics Corp (UTHR) Q4 20 Estimate To 2.04 From 2.08
5/2/2019 9:41:23 AM Wedbush Is Lowering United Therapeutics Corp (UTHR) Q3 20 Estimate To 2.52 From 2.59
5/2/2019 9:41:13 AM Wedbush Is Lowering United Therapeutics Corp (UTHR) Q2 20 Estimate To 2.46 From 2.52
5/2/2019 9:41:03 AM Wedbush Is Lowering United Therapeutics Corp (UTHR) Q1 20 Estimate To 2.77 From 2.83
5/2/2019 9:40:49 AM Wedbush Is Cutting United Therapeutics Corp (UTHR) Q4 19 Estimate To 1.88 From 1.93
5/2/2019 9:40:35 AM Wedbush Is Cutting United Therapeutics Corp (UTHR) Q3 19 Estimate To 2.43 From 2.47
5/2/2019 9:40:24 AM Wedbush Is Cutting United Therapeutics Corp (UTHR) Q2 19 Estimate To 2.46 From 2.51
5/2/2019 9:39:51 AM Wedbush Reiterates United Therapeutics Corp (UTHR) At Outperform With $273 Up From $269 Price Target
9/27/2018 6:38:05 AM Wedbush Reiterates United Therapeutics Corp (UTHR) At Outperform With $253 Price Target
2/27/2018 8:12:55 PM Wedbush Reiterates United Therapeutics Corp (UTHR) At Outperform With #234 Up From $232 Price Target